Highlights| April 03 2023 Selected Articles from This Issue Author & Article Information Online ISSN: 1538-8514 Print ISSN: 1535-7163 ©2023 American Association for Cancer Research2023American Association for Cancer Research Mol Cancer Ther (2023) 22 (4): 419. https://doi.org/10.1158/1535-7163.MCT-22-4-HI Related Content A commentary has been published: Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors A commentary has been published: Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts A commentary has been published: Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors View more A commentary has been published: SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record April 3 2023 Citation Selected Articles from This Issue. Mol Cancer Ther 1 April 2023; 22 (4): 419. https://doi.org/10.1158/1535-7163.MCT-22-4-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Antibody-drug conjugates (ADCs) are cancer therapeutics that combine antigen specificity and potent cytotoxicity in a single molecule. Melanotransferrin (CD228, MELTF) may hold promise as a cancer target due to its expression profile across multiple cancer indications. Here, Mazahreh and colleagues characterize the promising preclinical antitumor efficacy of the CD228-directed ADC SGN-CD228A. Using in vitro modeling, they demonstrate that SGN-CD228A activity is influenced by both CD228 expression and intrinsic MMAE sensitivity and show that the glucuronide linker confers retention of intracellular MMAE. These findings suggest that drug-linker properties and payload sensitivity are important parameters for ADC therapeutics. PARP inhibitors have improved the treatment of ovarian cancer, but resistance limits their effectiveness. Tumor microenvironment and its response to treatment are crucial factors in PARPi resistance. Here, Jin and colleagues have identified therapy-induced senescence (TIS) in cancer-associated fibroblasts (CAFs) promote tumor resistance through senescence associated secretion phenotype (SASP). Furthermore, antihistamine bepotastine showed inhibitory... You do not currently have access to this content.